Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

In this I am with you, Infinity. Based on what competition has done the science looks to be there. Aprea has even show p53 based efficacy in ovarian cancer. What IPIX needed was to do the same and only after that go for oral formulation. But, it seems that whenever IPIX gets really close to a major triumph they just need to do one amateurish (well, at least avoidable) plunder first.

Evidence:
1. Going after oral K formulation instead of putting Kevetrin in IV with a known cancer drug to show improvement in efficacy a la APREA - doxorubicin is dirt cheap. Try with that. Aprea did. As a result they now have funding and are going ahead with Sloan Kettering. I would not call that a bad outcome for an experiment with an old drug.
2. Misreading dosing range info from prurisol safety studies and ending with wrong dosing range in p2 trial. I mean it looks like they expected 100 mg and 200 mg arms combined being about 20 percentage points or more effective than placebo in PASI75. By their design that would have produced p < 0.05. PoC - Done - Let's talk about some funding. Instead they need to run pIIb with dosing range they should have used to begin with.
3. Brilacidin is probably THE DRUG in their arsenal that would benefit big time from oral formulation so that they could go after upper intestines and UC in addition to UP (and that just for starters). Is it getting it? Dunno! But I know somebody is putting it in pouches. And those are hard to swallow - literally and figuratively. And not really needed for SOM p3.

Don't take me wrong. I think that IPIX will eventually get where it is aiming at. These crazy timings (or missteps, if you like) are just so annoying.